Isomorphic Labs, the AI-driven drug discovery company under Google parent Alphabet (NASDAQ: GOOG), has announced the completion of a $5 billion Series C funding round, according to a report.
The round was co-led by Greenoaks and Sequoia Capital, with new investors including a16z participating, while Alphabet (NASDAQ: GOOGL) continued to make a substantial capital injection. Existing investors Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund all followed on. The company did not disclose its valuation in the announcement.
According to public information, Isomorphic Labs was spun out from the Google DeepMind ecosystem in 2021 and is headquartered in London, UK, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland. Its founder and CEO is Demis Hassabis, a 2024 Nobel Prize in Chemistry laureate and co-founder of DeepMind.
The company's core asset is its drug design engine IsoDDE, which integrates foundational models for structure prediction, binding pocket identification, and affinity prediction. Its oncology and immunology proprietary programs and partnered programs have already produced preclinical results.
Previously, the company completed a $600 million first external funding round in March 2025 and a $2.1 billion Series B round in May 2026, bringing cumulative financing to approximately $7.7 billion. Currently, no proprietary drug has entered human clinical trials.
Comments